Serveur d'exploration autour de Joseph Jankovic

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The evolution of diagnosis in early Parkinson Disease

Identifieur interne : 000004 ( PascalFrancis/Curation ); précédent : 000003; suivant : 000005

The evolution of diagnosis in early Parkinson Disease

Auteurs : J Jankovic [États-Unis] ; A Rajput [Canada] ; M Mcdermott [États-Unis] ; D Perl [États-Unis]

Source :

RBID : Pascal:00-0183232

Descripteurs français

English descriptors

Abstract

Context: Since there is no diagnostic biological marker for Parkinson disease (PD), the diagnosis is based on the results of clinical assessment. The accuracy of diagnosis improves with time and repeated assessments. Studies that require only inclusion of early cases of PD present a diagnostic challenge. Previous studies concluded that initial diagnoses of PD made by general neurologists were incorrect in 24% to 35% of the cases when patients were examined at autopsy. Experts in movement disorders are expected to have greater accuracy of initial diagnosis of PD. Objective: To determine the evolution of clinical diagnosis in patients with early PD made initially by experts in PD. Design: Eight hundred patients with mild parkinsonian symptoms (Hoehn and Yahr stage 1 or 2) who received a diagnosis of PD less than 5 years before the beginning of the study were included in the original Deprenyl and Tocopherol Antioxidative Therapy for Parkinsons Disease study. These patients were followed up prospectively with repeated clinical assessments. The following clinical criteria were used to reassess the initial diagnosis: investigator's confidence in the diagnosis of PD, presence of atypical clinical features, findings of imaging studies, response to levodopa, and results of autopsy examinations. Results: The mean ± SD duration of illness in the 800 cases at enrollment was 2.2 ± 1.3 years, and the mean ± SD Hoehn and Yahr stage was 1.6 ± 0.5. The mean ± SD follow-up was 6.0 ± 1.4 years (range, 0.2-7.6 years). In 5 cases, PD was not confirmed at autopsy, and in 15 patients, the results of imaging studies indicated the presence of other pathological conditions. Of the 550 cases treated with levodopa, 49 (8.9%) had little or no improvement; 6 of these cases overlap with either autopsy or imaging study exclusion criteria. Two other cases had at least 4 of the 6 atypical clinical features arguing against the diagnosis of PD. Thus, of the 800 patients, 65 (8.1%) did not have PD according to the study criteria. Compared with those patients with the final diagnosis of PD, in the diagnoses of 60 patients without autopsy, the duration of symptoms (mean ± SD, 7.2 ± 2.0 years vs 8.3 ± 1.9 years; P<.001) and the duration of follow-up (5.3 ± 1.6 years vs 6.1 ± 1.3 years; P<.001) were shorter. Conclusions: We found that 65 (8.1%) of patients initially diagnosed as having PD were later found to have an alternate diagnosis based on multifactorial clinical diagnostic criteria. This alternate diagnosis indicated that experts in PD changed their diagnoses infrequently during the 7.6-year follow-up.
pA  
A01 01  1    @0 0003-9942
A02 01      @0 ARNEAS
A03   1    @0 Arch. neurol. : (Chic.)
A05       @2 57
A06       @2 3
A08 01  1  ENG  @1 The evolution of diagnosis in early Parkinson Disease
A11 01  1    @1 JANKOVIC (J.)
A11 02  1    @1 RAJPUT (A. H.)
A11 03  1    @1 MCDERMOTT (M. P.)
A11 04  1    @1 PERL (D. P.)
A14 01      @1 Department of Neurology, Baylor College of Medicine @2 Houston, Tex @3 USA @Z 1 aut.
A14 02      @1 Department of Medicine, Royal University Hospital, University of Saskatchewan @2 Saskatoon @3 CAN @Z 2 aut.
A14 03      @1 Department of Biostatistics, University of Rochester School of Medicine and Dentistry @2 Rochester, NY @3 USA @Z 3 aut.
A14 04      @1 Department of Pathology (Neuropathology), Mount Sinai School of Medicine @2 New York, NY @3 USA @Z 4 aut.
A17 01  1    @1 Parkinson Study Group @3 USA
A20       @1 369-372
A21       @1 2000
A23 01      @0 ENG
A43 01      @1 INIST @2 2048B @5 354000082247440120
A44       @0 0000 @1 © 2000 INIST-CNRS. All rights reserved.
A45       @0 29 ref.
A47 01  1    @0 00-0183232
A60       @1 P
A61       @0 A
A64 01  1    @0 Archives of neurology : (Chicago)
A66 01      @0 USA
C01 01    ENG  @0 Context: Since there is no diagnostic biological marker for Parkinson disease (PD), the diagnosis is based on the results of clinical assessment. The accuracy of diagnosis improves with time and repeated assessments. Studies that require only inclusion of early cases of PD present a diagnostic challenge. Previous studies concluded that initial diagnoses of PD made by general neurologists were incorrect in 24% to 35% of the cases when patients were examined at autopsy. Experts in movement disorders are expected to have greater accuracy of initial diagnosis of PD. Objective: To determine the evolution of clinical diagnosis in patients with early PD made initially by experts in PD. Design: Eight hundred patients with mild parkinsonian symptoms (Hoehn and Yahr stage 1 or 2) who received a diagnosis of PD less than 5 years before the beginning of the study were included in the original Deprenyl and Tocopherol Antioxidative Therapy for Parkinsons Disease study. These patients were followed up prospectively with repeated clinical assessments. The following clinical criteria were used to reassess the initial diagnosis: investigator's confidence in the diagnosis of PD, presence of atypical clinical features, findings of imaging studies, response to levodopa, and results of autopsy examinations. Results: The mean ± SD duration of illness in the 800 cases at enrollment was 2.2 ± 1.3 years, and the mean ± SD Hoehn and Yahr stage was 1.6 ± 0.5. The mean ± SD follow-up was 6.0 ± 1.4 years (range, 0.2-7.6 years). In 5 cases, PD was not confirmed at autopsy, and in 15 patients, the results of imaging studies indicated the presence of other pathological conditions. Of the 550 cases treated with levodopa, 49 (8.9%) had little or no improvement; 6 of these cases overlap with either autopsy or imaging study exclusion criteria. Two other cases had at least 4 of the 6 atypical clinical features arguing against the diagnosis of PD. Thus, of the 800 patients, 65 (8.1%) did not have PD according to the study criteria. Compared with those patients with the final diagnosis of PD, in the diagnoses of 60 patients without autopsy, the duration of symptoms (mean ± SD, 7.2 ± 2.0 years vs 8.3 ± 1.9 years; P<.001) and the duration of follow-up (5.3 ± 1.6 years vs 6.1 ± 1.3 years; P<.001) were shorter. Conclusions: We found that 65 (8.1%) of patients initially diagnosed as having PD were later found to have an alternate diagnosis based on multifactorial clinical diagnostic criteria. This alternate diagnosis indicated that experts in PD changed their diagnoses infrequently during the 7.6-year follow-up.
C02 01  X    @0 002B17G
C03 01  X  FRE  @0 Parkinson maladie @5 01
C03 01  X  ENG  @0 Parkinson disease @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @5 01
C03 02  X  FRE  @0 Précoce @5 16
C03 02  X  ENG  @0 Early @5 16
C03 02  X  SPA  @0 Precoz @5 16
C03 03  X  FRE  @0 Diagnostic @5 17
C03 03  X  ENG  @0 Diagnosis @5 17
C03 03  X  SPA  @0 Diagnóstico @5 17
C03 04  X  FRE  @0 Evolution @5 18
C03 04  X  ENG  @0 Evolution @5 18
C03 04  X  SPA  @0 Evolución @5 18
C03 05  X  FRE  @0 Homme @5 20
C03 05  X  ENG  @0 Human @5 20
C03 05  X  SPA  @0 Hombre @5 20
C07 01  X  FRE  @0 Système nerveux pathologie @5 37
C07 01  X  ENG  @0 Nervous system diseases @5 37
C07 01  X  SPA  @0 Sistema nervioso patología @5 37
C07 02  X  FRE  @0 Système nerveux central pathologie @5 38
C07 02  X  ENG  @0 Central nervous system disease @5 38
C07 02  X  SPA  @0 Sistema nervosio central patología @5 38
C07 03  X  FRE  @0 Encéphale pathologie @5 39
C07 03  X  ENG  @0 Cerebral disorder @5 39
C07 03  X  SPA  @0 Encéfalo patología @5 39
C07 04  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 04  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 04  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 05  X  FRE  @0 Maladie dégénérative @5 41
C07 05  X  ENG  @0 Degenerative disease @5 41
C07 05  X  SPA  @0 Enfermedad degenerativa @5 41
N21       @1 136

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:00-0183232

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">The evolution of diagnosis in early Parkinson Disease</title>
<author>
<name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Tex</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Rajput, A H" sort="Rajput, A H" uniqKey="Rajput A" first="A" last="Rajput">A Rajput</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Medicine, Royal University Hospital, University of Saskatchewan</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Mcdermott, M P" sort="Mcdermott, M P" uniqKey="Mcdermott M" first="M" last="Mcdermott">M Mcdermott</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Biostatistics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Perl, D P" sort="Perl, D P" uniqKey="Perl D" first="D" last="Perl">D Perl</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Department of Pathology (Neuropathology), Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">00-0183232</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0183232 INIST</idno>
<idno type="RBID">Pascal:00-0183232</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000162</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000004</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">The evolution of diagnosis in early Parkinson Disease</title>
<author>
<name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Tex</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Rajput, A H" sort="Rajput, A H" uniqKey="Rajput A" first="A" last="Rajput">A Rajput</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Medicine, Royal University Hospital, University of Saskatchewan</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author>
<name sortKey="Mcdermott, M P" sort="Mcdermott, M P" uniqKey="Mcdermott M" first="M" last="Mcdermott">M Mcdermott</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Department of Biostatistics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Perl, D P" sort="Perl, D P" uniqKey="Perl D" first="D" last="Perl">D Perl</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Department of Pathology (Neuropathology), Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
<imprint>
<date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Archives of neurology : (Chicago)</title>
<title level="j" type="abbreviated">Arch. neurol. : (Chic.)</title>
<idno type="ISSN">0003-9942</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Diagnosis</term>
<term>Early</term>
<term>Evolution</term>
<term>Human</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Précoce</term>
<term>Diagnostic</term>
<term>Evolution</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Context: Since there is no diagnostic biological marker for Parkinson disease (PD), the diagnosis is based on the results of clinical assessment. The accuracy of diagnosis improves with time and repeated assessments. Studies that require only inclusion of early cases of PD present a diagnostic challenge. Previous studies concluded that initial diagnoses of PD made by general neurologists were incorrect in 24% to 35% of the cases when patients were examined at autopsy. Experts in movement disorders are expected to have greater accuracy of initial diagnosis of PD. Objective: To determine the evolution of clinical diagnosis in patients with early PD made initially by experts in PD. Design: Eight hundred patients with mild parkinsonian symptoms (Hoehn and Yahr stage 1 or 2) who received a diagnosis of PD less than 5 years before the beginning of the study were included in the original Deprenyl and Tocopherol Antioxidative Therapy for Parkinsons Disease study. These patients were followed up prospectively with repeated clinical assessments. The following clinical criteria were used to reassess the initial diagnosis: investigator's confidence in the diagnosis of PD, presence of atypical clinical features, findings of imaging studies, response to levodopa, and results of autopsy examinations. Results: The mean ± SD duration of illness in the 800 cases at enrollment was 2.2 ± 1.3 years, and the mean ± SD Hoehn and Yahr stage was 1.6 ± 0.5. The mean ± SD follow-up was 6.0 ± 1.4 years (range, 0.2-7.6 years). In 5 cases, PD was not confirmed at autopsy, and in 15 patients, the results of imaging studies indicated the presence of other pathological conditions. Of the 550 cases treated with levodopa, 49 (8.9%) had little or no improvement; 6 of these cases overlap with either autopsy or imaging study exclusion criteria. Two other cases had at least 4 of the 6 atypical clinical features arguing against the diagnosis of PD. Thus, of the 800 patients, 65 (8.1%) did not have PD according to the study criteria. Compared with those patients with the final diagnosis of PD, in the diagnoses of 60 patients without autopsy, the duration of symptoms (mean ± SD, 7.2 ± 2.0 years vs 8.3 ± 1.9 years; P<.001) and the duration of follow-up (5.3 ± 1.6 years vs 6.1 ± 1.3 years; P<.001) were shorter. Conclusions: We found that 65 (8.1%) of patients initially diagnosed as having PD were later found to have an alternate diagnosis based on multifactorial clinical diagnostic criteria. This alternate diagnosis indicated that experts in PD changed their diagnoses infrequently during the 7.6-year follow-up.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0003-9942</s0>
</fA01>
<fA02 i1="01">
<s0>ARNEAS</s0>
</fA02>
<fA03 i2="1">
<s0>Arch. neurol. : (Chic.)</s0>
</fA03>
<fA05>
<s2>57</s2>
</fA05>
<fA06>
<s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>The evolution of diagnosis in early Parkinson Disease</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>JANKOVIC (J.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>RAJPUT (A. H.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>MCDERMOTT (M. P.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>PERL (D. P.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Tex</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Medicine, Royal University Hospital, University of Saskatchewan</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Department of Biostatistics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Department of Pathology (Neuropathology), Mount Sinai School of Medicine</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1">
<s1>Parkinson Study Group</s1>
<s3>USA</s3>
</fA17>
<fA20>
<s1>369-372</s1>
</fA20>
<fA21>
<s1>2000</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>2048B</s2>
<s5>354000082247440120</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>00-0183232</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Archives of neurology : (Chicago)</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Context: Since there is no diagnostic biological marker for Parkinson disease (PD), the diagnosis is based on the results of clinical assessment. The accuracy of diagnosis improves with time and repeated assessments. Studies that require only inclusion of early cases of PD present a diagnostic challenge. Previous studies concluded that initial diagnoses of PD made by general neurologists were incorrect in 24% to 35% of the cases when patients were examined at autopsy. Experts in movement disorders are expected to have greater accuracy of initial diagnosis of PD. Objective: To determine the evolution of clinical diagnosis in patients with early PD made initially by experts in PD. Design: Eight hundred patients with mild parkinsonian symptoms (Hoehn and Yahr stage 1 or 2) who received a diagnosis of PD less than 5 years before the beginning of the study were included in the original Deprenyl and Tocopherol Antioxidative Therapy for Parkinsons Disease study. These patients were followed up prospectively with repeated clinical assessments. The following clinical criteria were used to reassess the initial diagnosis: investigator's confidence in the diagnosis of PD, presence of atypical clinical features, findings of imaging studies, response to levodopa, and results of autopsy examinations. Results: The mean ± SD duration of illness in the 800 cases at enrollment was 2.2 ± 1.3 years, and the mean ± SD Hoehn and Yahr stage was 1.6 ± 0.5. The mean ± SD follow-up was 6.0 ± 1.4 years (range, 0.2-7.6 years). In 5 cases, PD was not confirmed at autopsy, and in 15 patients, the results of imaging studies indicated the presence of other pathological conditions. Of the 550 cases treated with levodopa, 49 (8.9%) had little or no improvement; 6 of these cases overlap with either autopsy or imaging study exclusion criteria. Two other cases had at least 4 of the 6 atypical clinical features arguing against the diagnosis of PD. Thus, of the 800 patients, 65 (8.1%) did not have PD according to the study criteria. Compared with those patients with the final diagnosis of PD, in the diagnoses of 60 patients without autopsy, the duration of symptoms (mean ± SD, 7.2 ± 2.0 years vs 8.3 ± 1.9 years; P<.001) and the duration of follow-up (5.3 ± 1.6 years vs 6.1 ± 1.3 years; P<.001) were shorter. Conclusions: We found that 65 (8.1%) of patients initially diagnosed as having PD were later found to have an alternate diagnosis based on multifactorial clinical diagnostic criteria. This alternate diagnosis indicated that experts in PD changed their diagnoses infrequently during the 7.6-year follow-up.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Précoce</s0>
<s5>16</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Early</s0>
<s5>16</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Precoz</s0>
<s5>16</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Diagnostic</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Diagnosis</s0>
<s5>17</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Diagnóstico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Evolution</s0>
<s5>18</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Evolution</s0>
<s5>18</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Evolución</s0>
<s5>18</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21>
<s1>136</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000004 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000004 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:00-0183232
   |texte=   The evolution of diagnosis in early Parkinson Disease
}}

Wicri

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024